Jane Street’s Apimeds Pharmaceuticals US APUS Stock Holding History

Jane Street’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.4K	Buy	+1,599	New	+$21.8K	﹤0.01%	11264
2026 Q1	–	Sell	-2,719	Closed	-$44.6K	–	13464
2025 Q4	$44.6K	Buy	+2,719	New	+$58K	﹤0.01%	10540

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jane Street's APUS Position: Q2 2026 in Review

Jane Street opened a new position in Apimeds Pharmaceuticals US (APUS) in Q2 2026: 1,599 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #11264 among its holdings. This is a return to the name: Jane Street previously reported a position in APUS as recently as Q4 2025.

Jane Street first reported a position in APUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $44.6K in Q4 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

Jane Street held 1,599 shares of Apimeds Pharmaceuticals US worth $14.4K as of Q2 2026.
Apimeds Pharmaceuticals US was a new Jane Street position in Q2 2026.
Apimeds Pharmaceuticals US made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11264 holding.
Jane Street first reported a position in Apimeds Pharmaceuticals US in Q4 2025 and has held it in 2 quarters since.
Jane Street's Apimeds Pharmaceuticals US position peaked at $44.6K in Q4 2025.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.